G. OʼConnell - Concepedia

Author

G. OʼConnell

Also Known As

G J O'Connell, G O'Connell, G. J. O'Connell, G. O'Connell, G. O'connell, G. OʼConnell, G.J. O'CONNELL, G.J. O'Connell, Gregory J. O'Connell, Gregory O'Connell

Publications

858

Citations

H-Index

Concepts

All Affiliations

McMaster University Ontario Institute for Cancer Research University of Toronto

About

G. OʼConnell is an author at McMaster University specializing in medicine, radiation oncology, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	280
2	Public Health	5	5	221
3	Endocrinology	3	3	109
4	Cell Biology	2	2	52
5	Engineering	1	1	11

G. OʼConnell

Publications

553

Citations

H-Index

Page 1

	Year	Citations
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. K. Swenerton, J Jeffrey, Gavin Stuart, Journal of Clinical Oncology	1992	214
Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. G. OʼConnell, Eamonn D. Ryan, Kieran J. Murphy, PubMed Surgical OncologyPelvic Reconstructive SurgeryGynecologyPredictive ValueGynecology Oncology	1987	85
Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat. John Jarrell, Eleonora Lai, RM Barr, PubMed Hormonal ContraceptiveFertilityLocal IrradiationReproductive HealthVaginal Opening	1987	77
Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor James J. Rusthoven, Leslie Levin, E. Eisenhauer, JNCI Journal of the National Cancer Institute	1991	29
A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma Hal W. Hirte, D.A. Clark, J. Mazurka, Gynecologic Oncology Cell CultureTumor CellsCell BiologyOvarian CarcinomaAscitic Fluid	1992	27
Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody Holger W. Hirte, David A. Clark, G. OʼConnell, Cellular Immunology Growth Factor-βCancer ImmunosurveillanceImmune RegulationImmunologyTumor Immunity	1992	25
Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy. W Shelley, A A Starreveld, JA Carmichael, PubMed Cisplatin/cyclophosphamide TherapySurgical OncologyColorectal SurgeryGastroenterologyGynecology	1988	21
Paraganglioma of the Vulva Terence J. Colgan, Irving Dardick, G. OʼConnell International Journal of Gynecological Pathology	1991	19
Effects of ionizing radiation and pretreatment with [D-Leu6,des-Gly10] luteinizing hormone-releasing hormone ethylamide on developing rat ovarian follicles. John Jarrell, E.V. YoungLai, Avril McMahon, PubMed Hormonal ContraceptiveFertilityHormone-releasing Hormone EthylamideReproductive HealthFemale Reproductive Function	1987	18
An analysis of the effects of increasing doses of ionizing radiation to the exteriorized rat ovary on follicular development, atresia, and serum gonadotropin levels John Jarrell, E.V. YoungLai, Ronald D. Barr, American Journal of Obstetrics and Gynecology InfertilityDevelopmental BiologyFertilityGonadotropin LevelsExteriorized Rat	1986	14

Page 1